Anavex Life Sciences’ (AVXL) Buy Rating Reaffirmed at D. Boral Capital

D. Boral Capital restated their buy rating on shares of Anavex Life Sciences (NASDAQ:AVXL) in a research note published on Monday morning,Benzinga reports. D. Boral Capital currently has a $46.00 price target on the biotechnology company’s stock.

Separately, HC Wainwright restated a “buy” rating and set a $40.00 target price on shares of Anavex Life Sciences in a research report on Monday, November 4th.

Anavex Life Sciences Stock Performance

Shares of Anavex Life Sciences stock opened at $9.03 on Monday. The company has a market cap of $765.74 million, a P/E ratio of -18.10 and a beta of 0.60. Anavex Life Sciences has a one year low of $3.25 and a one year high of $10.45. The firm has a fifty day moving average of $6.54 and a two-hundred day moving average of $5.62.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. SG Americas Securities LLC purchased a new stake in shares of Anavex Life Sciences during the second quarter worth $57,000. Orion Capital Management LLC lifted its stake in Anavex Life Sciences by 666.7% in the 3rd quarter. Orion Capital Management LLC now owns 11,500 shares of the biotechnology company’s stock worth $65,000 after purchasing an additional 10,000 shares in the last quarter. PVG Asset Management Corp bought a new position in Anavex Life Sciences in the 3rd quarter valued at $74,000. Atria Investments Inc purchased a new position in shares of Anavex Life Sciences during the third quarter worth about $76,000. Finally, Fiduciary Alliance LLC grew its position in Anavex Life Sciences by 45.2% in the second quarter. Fiduciary Alliance LLC now owns 19,275 shares of the biotechnology company’s stock worth $80,000 after acquiring an additional 6,000 shares in the last quarter. Institutional investors and hedge funds own 31.55% of the company’s stock.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.